NTLAIntellia Therapeutics, Inc.

$2B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$58M+59.6% YoY

Gross Profit

$48M82.2% margin

Operating Income

-$534M-923.1% margin

Net Income

-$519M-896.8% margin

EPS (Diluted)

$-5.25

Cash Flow

Operating Cash Flow

-$349M

Free Cash Flow

-$355M

Stock-Based Comp.

$154M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$319M

Stockholders' Equity

$872M

Cash & Equivalents

$189M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$58M	$36M	+59.6%
Gross Profit	$48M	$27M	+74.3%
Operating Income	-$534M	-$515M	-3.7%
Net Income	-$519M	-$481M	-7.9%

NTLA FY 2024 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena